Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Inactive patch Clear all
Recruiting Not applicable Interventional

A Study of the Jovi Patch, Powered by Signal Relief, for the Improvement of General Menstrual Discomfort

NCT07825558
View directory record Official record
Conditions
General Menstrual Discomfort
Interventions
Jovi Patch, Sham Patch
Device
Lead sponsor
Signal Relief
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Meadowbrook, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 19, 2026, 1:16 PM EDT
Withdrawn Not applicable Interventional

Lidocaine Patch for Relief of Pain During Epidural Placement in Laboring Patients

NCT01307839
View directory record Official record
Conditions
Pregnant, Labor
Interventions
5% lidocaine patch, placebo patch
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Oct 19, 2026, 1:16 PM EDT
Completed Phase 4 Interventional Results available

Effect of Perimenstrual Ovarian Steroid Supplementation on Perimenstrual Suicidality

NCT03720847
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Estradiol Transdermal Patch 0.1 mg/24 hrs, Oral Micronized Progesterone, Inactive Clear Patch, Placebo capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 19, 2026, 1:16 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Transdermal Nicotine in Female Patients at High Risk for Post Operative Nausea and/or Vomiting (PONV)

NCT00775749
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
transdermal nicotine patch, placebo patch
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 19, 2026, 1:16 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy

NCT02636699
View directory record Official record
Conditions
Peanut Allergy
Interventions
Viaskin Peanut 250mcg, Placebo
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
4 Years to 11 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Little Rock, Arkansas • San Diego, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 19, 2026, 1:16 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Observing Performance of Haptic Vibrotactile Trigger Technology by Measuring Changes in Resting Metabolic Rate: Assessment and Analysis

NCT07781384
View directory record Official record
Conditions
Resting Metabolic Rate, Energy Metabolism, Haptic Technology, Vibrotactile Stimulation
Interventions
IGNITE Patch (Active), Inactive patch
Device
Lead sponsor
SuperPatch Limited LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tyrone, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 19, 2026, 1:16 PM EDT
Completed Phase 4 Interventional

Postoperative Pain Control With Fentanyl Patch in Patients Undergoing Mastectomy and TRAM or DIEP Flap Reconstruction

NCT01258296
View directory record Official record
Conditions
Postoperative Pain After Breast Reconstruction With Abdominal Flap
Interventions
Fentanyl, Inactive patch
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 19, 2026, 1:16 PM EDT
Active, not recruiting Not applicable Interventional

The Precision CAD Trial

NCT04755413
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Medical/Behavioral therapy, Standard of Care, Registry
Other
Lead sponsor
Emory University
Other
Eligibility
21 Years to 90 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
5
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 19, 2026, 1:16 PM EDT
Recruiting Phase 3 Interventional

Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea

NCT06533865
View directory record Official record
Conditions
FHA (Functional Hypothalamic Amenorrhea)
Interventions
Romosozumab, Placebo, Zoledronic acid
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 30 Years · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 19, 2026, 1:16 PM EDT
Completed Phase 4 Interventional Results available

Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental Approach

NCT04112368
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Estradiol Transdermal Patch 0.1 mg/24 hrs, Oral Micronized Progesterone 200mg, Inactive Clear Patch, Placebo capsule
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 19, 2026, 1:16 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women

NCT02042196
View directory record Official record
Conditions
Menopause, Aging
Interventions
KUVAN, Placebo, Cetrotide, Climara, Placebo transdermal patch
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 19, 2026, 1:16 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Cardiometabolic Consequences of the Loss of Ovarian Function

NCT06264882
View directory record Official record
Conditions
Menopause, Estrogen Deficiency, Aging, Adiposity
Interventions
Degarelix, Transdermal Estradiol Patch, Transdermal Placebo Patch
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 19, 2026, 1:16 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Evaluating the Roles of Estrogen and Progesterone in Heart Metabolism

NCT00565916
View directory record Official record
Conditions
Postmenopausal Syndrome
Interventions
Estrogen, Progesterone, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
55 Years to 75 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 19, 2026, 1:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.

NCT06030297
View directory record Official record
Conditions
Peripheral Neuropathy
Interventions
Diode Laser fiber type Selective Stimulator, ZTlido 1.8 % Topical System, PeriCam PSI NR, Medoc Quantitative Sensory Testing, Inactive Topical System
Procedure · Drug · Diagnostic Test + 1 more
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Palo Alto, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 19, 2026, 1:16 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Hormone Replacement for Premature Ovarian Insufficiency

NCT02922348
View directory record Official record
Conditions
Primary Ovarian Insufficiency
Interventions
Hormone Replacement Therapy, Combined Oral Contraceptives
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
14 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 19, 2026, 1:16 PM EDT
Completed Phase 2 Interventional

Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis

NCT00836485
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Ketotifen 4.0% Patch, Placebo, Olopatadine 0.2%, Artificial tears
Drug
Lead sponsor
Senju USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 19, 2026, 1:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Performance Output With Haptics - Evaluating Athlete Response and Unrealized Potential

NCT06430879
View directory record Official record
Conditions
Muscle Strength, Muscle Weakness
Interventions
VICTORY PATCH, Sham Patch without VTT
Device
Lead sponsor
SuperPatch Limited LLC
Industry
Eligibility
18 Years to 30 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 19, 2026, 1:16 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Topiramate Alone and in Combination With the Nicotine Patch for Smoking Cessation: A Pilot Study

NCT00755716
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Placebo (sugar pill), Topiramate, Nicotine patch
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Oct 19, 2026, 1:16 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia

NCT01213524
View directory record Official record
Conditions
Tobacco Use Disorder, Schizophrenia
Interventions
sensorimotor replacement, 42 mg transdermal nicotine replacement, Placebo transdermal nicotine, usual brand smoking
Behavioral · Drug · Other
Lead sponsor
Brown University
Other
Eligibility
18 Years to 99 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 19, 2026, 1:16 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Iontophoresis in Psoriasis

NCT03979664
View directory record Official record
Conditions
Psoriasis, Psoriasis Vulgaris, Skin Diseases
Interventions
Activapatch intellidose 2.5 using active Iontophoresis, Activapatch intellidose 2.5 using inactive Iontophoresis, Dexamethasone
Device · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 19, 2026, 1:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Women's Health Initiative Silent Atrial Fibrillation Recording Study

NCT05366803
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Physical Activity
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
65 Years to 100 Years · Female only
Enrollment
1,257 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 19, 2026, 1:16 PM EDT
Recruiting Not applicable Interventional

Transcranial Direct Current Stimulation for Post Treatment Lyme Disease

NCT06915324
View directory record Official record
Conditions
Post-Treatment Lyme Disease
Interventions
Transcranial Direct Current Stimulation (tDCS), Cognitive training
Device · Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 19, 2026, 1:16 PM EDT
Completed Not applicable Interventional Results available

Evaluation of N-SWEAT Patch for Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating

NCT04599907
View directory record Official record
Conditions
Primary Axillary Hyperhidrosis
Interventions
Roll-In Cohort: Single Application of N-SWEAT Patch, Randomized Cohort: Single Application of N-SWEAT Patch, Randomized Cohort: Single Application of Sham Patch
Device
Lead sponsor
Candesant Biomedical, Inc.
Industry
Eligibility
22 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Encinitas, California • Fremont, California • Rockville, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 19, 2026, 1:16 PM EDT
Recruiting Phase 2 Interventional

Study of ALTO-101 in Patients With Schizophrenia

NCT06502964
View directory record Official record
Conditions
Schizophrenia, Cognitive Impairment
Interventions
ALTO-101, ALTO-101 Transdermal Delivery System, Placebo, Placebo Transdermal Delivery System
Drug · Device
Lead sponsor
Alto Neuroscience
Industry
Eligibility
21 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
14
States / cities
Garden Grove, California • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 19, 2026, 1:16 PM EDT